Notice for iptacopan (Novartis Pharmaceuticals Australia Pty Ltd)
Active ingredients
iptacopan
Date of review outcome
Lapse date
Type
Priority review
Indication
Treatment of adult patients with complement 3 glomerulopathy (C3G)
Therapeutic area
Nephrology